MTOR and multiple symmetric lipomatosis: These findings not only confirm the need for the Akt/mTOR pathway for the biologic functions of the MSL subtype, but also provide a predictive value of GBP5 for the therapeutic effectiveness of mTOR inhibitor on TNBC patients with MSL subtype.